TY - JOUR
AU - Edmondson, M.
AB - CLINICAL PHARMACOLOGY & THERAPEUTICS 2004;75(2) American Society for Clinical Pharmacology and Therapeutics P23 PI-76 PI-77 TREATING CHRONIC PEDIATRIC CONDITIONS: PIRENZ- DOSE-RESPONSE RELATIONSHIP OF INCREASING DOSES EPINE OPHTHALMIC GEL (PIR) FOR THE SLOWING OF PRO- OF DEXTROMETHORPHAN GIVEN TO CHILDREN WITH GRESSION OF PEDIATRIC MYOPIA AS A MODEL PEDIATRIC COUGH. I. M. Paul, MD, MSc, K. E. Yoder, S. A. Sturgis, RN, DEVELOPMENT PROGRAM. G. D. Novack, PhD, R. S. Crockett, CRNP, M. S. Baker, MD, M. L. Shaffer, PhD, C. M. Berlin, Jr., MD, PhD, P. Lopez, M. Edmondson, PharmaLogic Development, Inc., Pennsylvania State University, Hershey, PA. D.A.T.A., Inc., Valley Forge Pharmaceuticals, Inc., San Rafael, CA. Purpose: The efficacy of dextromethorphan (DM) for treating Purpose: There is a growing interest in developing drugs for the cough is uncertain, and its use is not supported by the American treatment of pediatric diseases. Combining pediatric development Academy of Pediatrics. Still, DM is often given to children as an with chronic use and prevention of disease progression indication(s) antitussive. Dosing of DM is based on age, not weight. We sought to present special challenges to the clinical pharmacologist. Myopia is a determine if a dose-response relationship existed among a cohort of very 
TI - Treating chronic pediatric conditions: pirenzepine ophthalmic gel (PIR) for the slowing of progression of pediatric myopia as a model pediatric development program
JF - Clinical Pharmacology & Therapeutics
DO - 10.1016/j.clpt.2003.11.086
DA - 2004-02-01
UR - https://www.deepdyve.com/lp/wiley/treating-chronic-pediatric-conditions-pirenzepine-ophthalmic-gel-pir-151GMphATw
SP - P23
EP - P23
VL - 75
IS - 2
DP - DeepDyve
ER -